Medivation (NASDAQ:MDVN) : Traders are bullish on Medivation (NASDAQ:MDVN) as it has outperformed the S&P 500 by a wide margin of 1.84% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.99%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 3.29% in the last 1 week, and is up 3.48% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The company shares have rallied 19.34% from its 1 Year high price. On Jul 7, 2016, the shares registered one year high at $62.98 and the one year low was seen on Feb 9, 2016. The 50-Day Moving Average price is $60.15 and the 200 Day Moving Average price is recorded at $47.34.
The stock has recorded a 20-day Moving Average of 3.97% and the 50-Day Moving Average is 3.69%.
Medivation (NASDAQ:MDVN): On Fridays trading session , Opening price of the stock was $62.92 with an intraday high of $62.92. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $61.99. However, the stock managed to close at $62.1, a loss of 1.02% for the day. On the previous day, the stock had closed at $62.74. The total traded volume of the day was 1,387,353 shares.
In an insider trading activity, The officer (SVP, General Counsel & Crp Sec), of Medivation, Inc., Powell Andrew Kenneth William had unloaded 2,578 shares at $60.42 per share in a transaction on June 6, 2016. The total value of transaction was $155,763. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company in collaboration with Astellas Pharma, Inc. has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe, and other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company in collaboration with Astellas is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. The Company has licensed exclusive worldwide rights to pidilizumab, an immune modulatory, anti-Programmed Death-1 (PD-1) monoclonal antibody for all potential indications from CureTech, Ltd.